NIH Archives - EverGlade

NIH

NIH’s Unified Funding Strategy Signals a New Approach to Award Decisions

The National Institutes of Health (NIH) is starting to roll out its new Unified Funding Strategy, originally announced in late 2025, to support more informed, transparent, and flexible funding decisions across its Institutes, Centers, and Offices. Peer review remains central to NIH’s process, but funding decisions will now draw on the full body of review […]

NIH’s Unified Funding Strategy Signals a New Approach to Award Decisions Read More »

NIAID Renews IMPAc‑TB to Accelerate Tuberculosis Vaccine Development 

Overview of the Opportunity The National Institute of Allergy and Infectious Diseases (NIAID), through the National Institutes of Health (NIH), has issued RFP No. BAA-75N93026R00008 for the Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc‑TB), a five‑year contract program that renews the effort to accelerate TB vaccine development. The goal is to define tissue‑specific and

NIAID Renews IMPAc‑TB to Accelerate Tuberculosis Vaccine Development  Read More »

The End of Mega Labs? What the Proposed NIH Grant Cap Means for Universities

For decades, the biomedical research landscape has been dominated by a relatively small number of highly funded, high-profile laboratories. It is a system that tends to reward past success with future funding. But a newly proposed policy from the National Institutes of Health (NIH) could fundamentally reshape how federal research dollars flow through the U.S.

The End of Mega Labs? What the Proposed NIH Grant Cap Means for Universities Read More »

NIH Guidance on International Subcontracting

Maximizing the Value of Foreign Collaborations While Safeguarding U.S. Investments The National Institutes of Health (NIH), the nation’s primary medical research agency, recently issued guidance on the use of international subcontractors in NIH-funded research. This announcement reflects NIH’s dual mission: advancing health outcomes for Americans while ensuring responsible stewardship of U.S. taxpayer dollars. While global

NIH Guidance on International Subcontracting Read More »

The NIH’s Strategic Plan for Autoimmune Disease Research

Enhancing Innovation, Collaboration, and Impact Autoimmune diseases are one of the most significant and complex public health challenges of our time. Affecting an estimated 23.5 to 50 million Americans, these conditions range from rheumatoid arthritis and type 1 diabetes to multiple sclerosis and lupus, impacting nearly every organ system and disproportionately affecting women (over 80%

The NIH’s Strategic Plan for Autoimmune Disease Research Read More »

NIH’s New Policy on AI and Proposal Limits: What You Need to Know

NIH just released NOT-OD-25-132: “Supporting Fairness and Originality in NIH Research Applications.” There are two major changes that will shape how you plan and submit proposals beginning September 25, 2025: Originality & AI: NIH reiterates that applications must be the investigators’ original work and flags risks from AI-generated text (e.g., plagiarism, fabricated citations). Institutions should

NIH’s New Policy on AI and Proposal Limits: What You Need to Know Read More »

NIH resume issuing grants

NIH Admits Funding Freeze Was Illegal, Resumes Issuing Grants

Overview In a major development for the biomedical research community, the National Institutes of Health (NIH) has officially acknowledged that its recent funding freeze was unlawful and has announced the resumption of grant distributions. This decision follows weeks of controversy and legal challenges, during which research institutions, universities, and lawmakers criticized the abrupt halt in

NIH Admits Funding Freeze Was Illegal, Resumes Issuing Grants Read More »

Court Blocks NIH Cap Indirect Cost Rate

Court Blocks NIH Cap on Indirect Cost Rates

Court Blocks NIH Cap on Indirect Cost Rates for Government Contracts In a significant development for research institutions and federal contractors, a federal judge has temporarily blocked the National Institutes of Health (NIH) from enforcing its cap on indirect cost rates. This decision comes as a result of a temporary restraining order (TRO) issued by

Court Blocks NIH Cap on Indirect Cost Rates Read More »

NIH Supplemental Guidance

Understanding the NIH Supplemental Guidance on Indirect Cost Rates

Overview The National Institutes of Health (NIH) has issued Supplemental Guidance to the 2024 NIH Grants Policy Statement regarding Indirect Cost Rates (NOT-OD-25-068). This update introduces a standardized 15% indirect cost rate for all applicable grants, aiming to streamline financial policies and enhance funding efficiency for research institutions. Purpose of the Guidance The primary objective

Understanding the NIH Supplemental Guidance on Indirect Cost Rates Read More »

Scroll to Top